Pascal Deschatelets - APELLIS PHARMACTDL Co-Founder, Chief Operating Officer
| 1JK Stock | EUR 31.28 0.82 2.55% |
COO
Pascal Deschatelets is Co-Founder, Chief Operating Officer of APELLIS PHARMACTDL 0001 since 2016.
| Age | 49 |
| Tenure | 8 years |
| Phone | 617 977 5700 |
| Web | http://www.apellis.com |
Pascal Deschatelets Latest Insider Activity
Tracking and analyzing the buying and selling activities of Pascal Deschatelets against APELLIS PHARMACTDL stock is an integral part of due diligence when investing in APELLIS PHARMACTDL. Pascal Deschatelets insider activity provides valuable insight into whether APELLIS PHARMACTDL is net buyers or sellers over its current business cycle. Note, APELLIS PHARMACTDL insiders must abide by specific rules, including filing SEC forms every time they buy or sell APELLIS PHARMACTDL'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Pascal Deschatelets six days ago Disposition of 874 shares by Pascal Deschatelets of Apellis Pharmaceuticals at 64.1382 subject to Rule 16b-3 | ||
Pascal Deschatelets over six months ago Disposition of 24500 shares by Pascal Deschatelets of Apellis Pharmaceuticals at 3.76 subject to Rule 16b-3 | ||
Pascal Deschatelets over six months ago Disposition of 69107 shares by Pascal Deschatelets of Apellis Pharmaceuticals at 3.76 subject to Rule 16b-3 |
APELLIS PHARMACTDL Management Efficiency
The company has return on total asset (ROA) of (0.4647) % which means that it has lost $0.4647 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (5.0711) %, meaning that it generated substantial loss on money invested by shareholders. APELLIS PHARMACTDL's management efficiency ratios could be used to measure how well APELLIS PHARMACTDL manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -5.07 | |||
| Return On Asset | -0.46 |
APELLIS PHARMACTDL 0001 Leadership Team
Elected by the shareholders, the APELLIS PHARMACTDL's board of directors comprises two types of representatives: APELLIS PHARMACTDL inside directors who are chosen from within the company, and outside directors, selected externally and held independent of APELLIS. The board's role is to monitor APELLIS PHARMACTDL's management team and ensure that shareholders' interests are well served. APELLIS PHARMACTDL's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, APELLIS PHARMACTDL's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Sullivan, Chief Financial Officer, Treasurer | ||
| Nicole Perry, Vice President - Finance | ||
| Adam Townsend, Chief Commercial Officer | ||
| Alec Machiels, Independent Director | ||
| Thomas Lackner, Senior Vice President Head of Europe | ||
| Paul Fonteyne, Independent Director | ||
| A Dunlop, Independent Director | ||
| Stephanie OBrien, Independent Director | ||
| Cedric Francois, President, Chief Executive Officer, Co-Founder, Director | ||
| Gerald Chan, Independent Chairman of the Board | ||
| David Watson, General Counsel, Vice President of Corporate Development | ||
| Victoria Brown, Senior Vice President Program Team Lead – Systemic Chronic | ||
| Pascal Deschatelets, Co-Founder, Chief Operating Officer | ||
| Federico Grossi, Chief Medical Officer | ||
| Lukas Scheibler, Chief Innovation Officer |
APELLIS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is APELLIS PHARMACTDL a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.07 | |||
| Return On Asset | -0.46 | |||
| Operating Margin | (4.60) % | |||
| Shares Outstanding | 110.58 M | |||
| Shares Owned By Insiders | 15.32 % | |||
| Shares Owned By Institutions | 89.16 % | |||
| Revenue | 113.05 M | |||
| Gross Profit | (253.92 M) | |||
| EBITDA | (518.43 M) | |||
| Net Income | (460.28 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in APELLIS Stock
APELLIS PHARMACTDL financial ratios help investors to determine whether APELLIS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in APELLIS with respect to the benefits of owning APELLIS PHARMACTDL security.